本帖最后由 老马 于 2012-1-13 21:20 编辑
7 d! `! a4 u8 H! i L& J: i- N: R3 H ?- ]
爱必妥和阿瓦斯丁的比较
3 N8 ]' O% m4 e, g' a/ S
& u |9 p$ U* c9 q; |7 J$ Rhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 L6 W2 C% F; |# d9 L8 n
$ V& V4 ^& }5 O; X
6 i) W/ |2 M. }. a* ?: y
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
9 @+ T$ w' F$ v& _3 C+ n$ V, d" M==================================================
* W& w- @4 d* h9 w2 }( eOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). U% E5 S! D0 o9 R0 w' E
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 f4 J v! F8 p3 o' EResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.; u6 r3 N+ t, m# Y6 y
|